Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Aim of this study was to observe
The study was adjusted in two parts:
PART 1 is a crossectional study in which the prevalance, risk factors and etiology of nocturia among postmenopausal women is assessed.
PART 2 is a cohort study observing the impact of 10 different hormonal substitution therapies on nocturia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Oral estrogen + IUD | Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + IUD |
| |
| Oral estrogen + hysterectomy | Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + hysterectomy. |
| |
| Oral estrogen + oral progesterone | Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + oral progesterone. |
| |
| Transdermal estrogen + IUD | Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + IUD. |
| |
| Transdermal estrogen + hysterectomy | Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + hysterectomy. |
| |
| Transdermal estrogen + oral progesteron | Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + oral progesteron |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Questionnaire | Other | All women fulfilled 3 questionairres
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in nocturnal Frequency | Change from baseline in nocturnal voiding episodes assessed via nycturia and menopause questionnaire | 6 months after initiating therapy |
| Measure | Description | Time Frame |
|---|---|---|
| Change in bother linked with nocturnal frequency | Change in VAS scale of bother linked with nocturnal frequency | 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Study is specific for postmenopausal women
Women who are biochochemically confirmed to be postmenopausal.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kim Pauwaert | Contact | 093321182 | kim.pauwaert@ugent.be | |
| Karel Everaert | Contact | Karel.Everaert@uzgent.be |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Urology, Ghent University | Recruiting | Ghent | Oost-Vlaanderen | 9000 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D053158 | Nocturia |
| ID | Term |
|---|---|
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D011795 | Surveys and Questionnaires |
| ID | Term |
|---|---|
| D003625 | Data Collection |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| SERM | Women who opt to be treated for their postmenopausal symptoms using SERM's |
|
| Aromatase inhibitor | Women who opt to be treated for their postmenopausal symptoms using aromatase inhibitor. |
|
| Duavive | Women who opt to be treated for their postmenopausal symptoms using duavive. |
|
| No treatment | Women who opt not to be treated for their postmenopausal symptoms. |
|
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |